In a study conducted in Taiwan, screening for HCC in the whole population and applying biochemistry testing plus AFP+US in a high-risk group (including patients with CHB) was a more cost-effective regimen than no screening [39]. This evidence concerns the gene AFP and hepatocellular carcinoma.